house 004


To make a donation

click here.

Logo Twitter T


Logo Instagram


Logo FB


I am in total awe of all those who helped to organise and participated in WalkWithMe 2014. When Olivia told me about her plans and the people involved, I knew it would be a success but I don’t think that even she and the wonderful WalkWithMe committee expected quite so many people to lace up their walking boots and to raise quite such a large sum. The £110,000 raised for Action Against Cancer has the potential to be transformational. The funds raised through WalkWithMe 2014 have enabled us to recruit a truly outstanding PhD student. One thing I love about science is that with 6 months of training a PhD student can be exploring unchartered territory, making discoveries at the very cutting edge of scientific knowledge. The WalkWithMe PhD Student, Giulia Lucchiari is helping us in our attempts to develop a treatment to block ‘LMTK3’, a gene we discovered and found to be central to both cancer causation and resistance to chemotherapy. This is hugely promising work and Giulia is already growing into a pivotal member of our team at Imperial College.


I am sure that WalkWithMe 2015 will be another great success and provide further vitally needed funding to drive forward our cancer drug discovery and development programmes at Imperial College. Good luck to all those taking part.


With love and gratitude


Justin Stebbing"


Professor Justin Stebbing's 2015 message


"The importance of thinking ‘outside the box’ is often overstated. One need not necessarily think outside the box to be a great business leader, financier, clinician or sportsman. It is often possible to succeed through doing what others are doing – only better. Research is different by its very definition – I think of it as the discovery of the unknown.

IMG_0754 IMG_0758 IMG_0783 IMG_0913 IMG_0914 IMG_0846 IMG_0958 IMG_0919 IMG_0916 IMG_0750 IMG_0954 IMG_0796

2015 in


2015 amount raised:


It was amazing that WalkWithMe 2015 raised £50,000! This crucial funding has contributed to exciting progress in the lab in the last year on our two main programmes: the development of an LMTK3 inhibiting drug, that could be eventually be one of the biggest breakthroughs in cancer medicine, and; understanding cancer stem cells, which are responsible for some of the most malignant features of this terrible disease.